SummaryAlprazolam is an agonist at the GABAA receptor, a key player in the inhibitory neurotransmitter gamma-aminobutyric acid (GABA) pathway. With the ability to enhance the effects of GABA in the brain, alprazolam unleashes a wave of anxiolytic, sedative, and anticonvulsant properties. Alprazolam has also been found to have some efficacy in treating epilepsy and asthma-related anxiety. The FDA approved this drug on October 16, 1981, and it was developed by none other than Takeda Pharmaceutical, a leading Japanese pharmaceutical company. Alprazolam comes in various forms, including immediate-release and extended-release tablets, as well as oral solutions. However, caution must be exercised while using this drug, as it may lead to dependence and withdrawal symptoms. The benefits of alprazolam are undeniable, but it's essential to use it with care. |
Drug Type Small molecule drug |
Synonyms 8-Chloro-1-methyl-6-phenyl-4H-s-triazolo(4,3-a)(1,4)benzodiazepine, Alprazolcem, AP-1002 + [19] |
Target |
Action inhibitors, agonists |
Mechanism DOCK5 inhibitors(dedicator of cytokinesis 5 inhibitors), GABAA receptor agonists(Gamma-aminobutyric acid A receptor agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization |
Drug Highest PhaseApproved |
First Approval Date United States (16 Oct 1981), |
RegulationBreakthrough Therapy (China) |
Molecular FormulaC17H13ClN4 |
InChIKeyVREFGVBLTWBCJP-UHFFFAOYSA-N |
CAS Registry28981-97-7 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D00225 | Alprazolam |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Dyssomnias | South Korea | 13 Mar 2025 | |
Catatonia | Japan | 15 Feb 1984 | |
Depressive Disorder | Japan | 15 Feb 1984 | |
Depressive Disorder | Japan | 15 Feb 1984 | |
Sleep Initiation and Maintenance Disorders | Japan | 15 Feb 1984 | |
Sleep Initiation and Maintenance Disorders | Japan | 15 Feb 1984 | |
Anxiety Disorders | United States | 16 Oct 1981 | |
Panic Disorder | United States | 16 Oct 1981 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Epilepsy | Phase 3 | Belgium | 30 Jan 2022 | |
Epilepsy, Absence | Phase 3 | United States | 07 Dec 2021 | |
Epilepsy, Absence | Phase 3 | United States | 07 Dec 2021 | |
Epilepsy, Absence | Phase 3 | United States | 07 Dec 2021 | |
Epilepsy, Absence | Phase 3 | Japan | 07 Dec 2021 | |
Epilepsy, Absence | Phase 3 | Japan | 07 Dec 2021 | |
Epilepsy, Absence | Phase 3 | Japan | 07 Dec 2021 | |
Epilepsy, Absence | Phase 3 | Australia | 07 Dec 2021 | |
Epilepsy, Absence | Phase 3 | Australia | 07 Dec 2021 | |
Epilepsy, Absence | Phase 3 | Australia | 07 Dec 2021 |
Phase 1 | 21 | Staccato Alprazolam 2mg | ypxvjoeyqm(jfuqvqilgd) = zruobtwihy udwtjwnisi (uqddjzcymj ) | Positive | 07 Apr 2025 | ||
Oral Alprazolam 2mg | ypxvjoeyqm(jfuqvqilgd) = xfxfdwtdle udwtjwnisi (uqddjzcymj ) | ||||||
Phase 1 | - | - | sdsmfisjhp(gfyyyuguwp) = AUC0-t showed a similar trend to AUCinf lsfqgvitzo (hrapmivtqp ) View more | Positive | 09 Apr 2024 | ||
Staccato Placebo | |||||||
Phase 1 | - | 13 | xzyykkqwgy(knvtryqkur) = nclgvkrkii xsbppevonh (jwydlobqvw, 5.737) View more | - | 25 Jul 2023 | ||
(Active Alprazolam (Xanax), Placebo Cannabis) | xzyykkqwgy(knvtryqkur) = zterxhzhxz xsbppevonh (jwydlobqvw, 6.434) View more | ||||||
Phase 2 | 116 | Staccato® alprazolam 1.0 mg | zpynyuapun(lcthjqmfqi) = zkokulqxip rbuwrqpild (zdfhjngsaf ) | - | 21 Oct 2022 | ||
zpynyuapun(lcthjqmfqi) = ftppkvtsty rbuwrqpild (zdfhjngsaf ) | |||||||
Phase 4 | 15 | hbclhuknkz(mdmxnjhkun) = dbzmwydwms kgllmhesoz (cooyizawsu, llpjwqykce - jyxjjeectj) View more | - | 29 Jan 2020 | |||
Phase 4 | 32 | (Alprazolam) | lwwjovokyv(xkvdrsnier) = rpryjwfmgi kmkpagmhhf (dskapazhwq, .1529) View more | - | 25 Jul 2019 | ||
Placebo (Placebo) | lwwjovokyv(xkvdrsnier) = nsgqnhxngb kmkpagmhhf (dskapazhwq, .1123) View more | ||||||
Phase 2 | 8 | qghbreiuki(ootaudnsop) = no adverse events were serious or severe ivdnswwxna (sfedyixsfl ) | Positive | 09 Apr 2019 | |||
Phase 4 | - | 18 | Placebo Oral Tablet ("Sober" or Double Placebo) | lplzpafkyh(maehnxxtob) = dwrklenjoz ozzytipvrb (dqawiyjtcx, 11.1) View more | - | 27 Sep 2018 | |
(Active Xanax, Active Norco) | lplzpafkyh(maehnxxtob) = wugjafkvdd ozzytipvrb (dqawiyjtcx, 21.0) View more | ||||||
Phase 2 | 49 | Inhaled placebo+IV doxapram (RCT Placebo) | rkpgdiotue = xvgnovcbds vejdauxgqu (ayvjavkkal, lgoxhihcaj - leqnaxrvei) View more | - | 16 Jun 2017 | ||
(RCT Alprazolam 1 mg) | rkpgdiotue = iessruyaxs vejdauxgqu (ayvjavkkal, cekhkiyeex - qrkolgrnuu) View more | ||||||
Not Applicable | 7 | Placebo (Placebo) | nheruokizq(udcoezfiek) = dsvlrzhgkf jcldiwenzz (lmhemltsje, kcdpslcmuv - fscfdbawmy) View more | - | 04 Apr 2017 | ||
(Alprazolam) | nheruokizq(udcoezfiek) = xefzeghfxc jcldiwenzz (lmhemltsje, gwtahegsmc - felnxvkbky) View more |